Publications 2010

1.

Al Hadithy AFY , Ivanova SA, Pechlivanoglou P, Wilffert B, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JRBJ, Loonen AJM.
Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia.
Hum Psychopharmacol Clin Exp 2010;25:84-91.

2.

Bakker MK , Kerstjens-Frederikse WS, Buys CHCM, de Walle HEK, de Jong-van den Berg LTW.
First-trimester use of paroxetine and congenital heart defects: A population-based case-control study.
Birth Defects Research Part A: Clinical Molecular Teratology 2010;88(2):94-100.

3.

Bakker MK , de Walle HEK, Wilffert B, de Jong-van den Berg LTW.
Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study.
Pharmacoepidemiology and Drug Safety 2010;19:808-13.

4.

Boersma C , Voors AA, Visser ST, de Jong-van den Berg LTW, Postma MJ.
Cost Effectiveness of Angiotensin Receptor Blocker Monotherapy in Patients with Hypertension in the Netherlands.
American Journal of Cardiovasc Drugs 2010;10(1):49-54.

5.

Boersma C , Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LTW, de Jong PE, Postma MJ.
Prevention of Renal and Vascular End Stage Disease Study Group. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Clinical Therapeutics 2010;32(6):1103-21.

6.

Boersma C , Broere A, Postma MJ.
Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis.
Value in Health 2010;13(6):853-6.

7.

Boonstra G , Grobbee DE, Hak E, Kahn RS, Burger H.
Initiation of antipsychotic treatment by general practitioners. A case-control study.
Journal of Evaluation in Clinical Practice 2010;doi:10.1111/j.1365-2753.2009.01352.x.

8.

Connolly MP, Postma MJ.
Health care as an investment: Implications for an era of ageing populations.
Journal of Medical Marketing 2010;10:5-14.

9.

Connolly MP , Ledger W, Postma MJ.
Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms.
Human Fertility 2010;13(1):13-8.

10.

Crijns HJMJ , Straus SM, Gispen-de Wied CH, de Jong-van den Berg LTW.
Compliance with Pregnancy Prevention Programs of isotretinoin in Europe: a systematic review .
British Journal of Dermatology 2010;DOI: 10.1111/j.1365-2133.2010.09976.x.

11.

de Vries TW , van den Berg PB, Duiverman EJ, de Jong-van den Berg LTW.
Effect of a minimal pharmacy intervention on improvement of adherence to asthma guidelines.
Archives of Disease in Childhood 2010;95:302-4.

12.

de Vries R , Kretzschmar M, Schellekens JFP, Versteegh FGA, Westra TA, Roord JJ, Postma MJ.
Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model.
Plos One 2010;5(10):e13392-DOI:10.1371/journal.pone.0013392.

13.

Duyvendak M , Naunton M, van Roon EN, Brouwers JRBJ.
Doctors' beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention.
Journal of Clinical Pharmacy and Therapeutics 2010;doi:10.1111/j.1365-2710.2010.01185.x.

14.

Eussen SRBM, van der Elst ME, Klungel OH, Rompelberg CJM, Garssen J, Oosterveld MH, de Boer A, de Gier JJ, Bouvy ML.
A Pharmaceutical Care Program to Improve Adherence to Statin Therapy: A Randomized Controlled Trial.
The Annals of Pharmacotherapy 2010;DOI 10.1345/aph.1P281.

15.

Faber A , Kalverdijk LJ, de Jong-van den Berg LTW, Hugtenburg JG, Minderaa RB, Tobi H.
Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands.
Eur Child Adolesc Psychiatry 2010;19:159-66.

16.

Gefenaite G , Munster JM, van Houdt R, Hak E.
Effectiveness of the Q fever vaccine: A meta-analysis.
Vaccine 2010;DOI:10.1016/j.vaccine.2010.11.008.

17.

Geurts MME , Pot JLW, Schepers EH, Tromp C, Colijn CG, Dijkstra A, de Gier JJ.
The evaluation of an intervention based on the application of patient self-completion concordance forms in Dutch community pharmacies and the effect on adherence to chronic medication.
Patient Education and Counseling 2010;78(1):85-90.

18.

Gorter KJ , Hak E, Zuithoff NPA, Hof H, Rutten GEHM.
Risk of recurrent acute lower urinary tract infections and prescription pattern of antibiotics in women with and without diabetes in primary care.
Family Practice 2010;27:379-85.

19.

Gorter KJ , Hak E, Gustafsson T, de Bruijn O, Rutten GEHM.
Management of infections in type 2 diabetes from the patient's perspective: A qualitative approach.
Primary Care Diabetes 2010;doi:10.1016/j.pcd.2010.09.003.

20.

Groenwold RHH , Nelson DB, Nichol KL, Hoes AW, Hak E.
Sensitivity analyses to estimate the potential impact of unmeasured confounding in causal research.
International Journal of Epidemiology 2010;39:107-17.

21.

Houweling H , Verweij M, Ruitenberg EJ, Postma MJ.
Criteria for inclusion of vaccinations in public programmes.
Vaccine 2010;28(17):2924-31.

22.

Jentink J , Loane MA, Dolk H, Barisic I, Garne E, Morris JK, de Jong-van den Berg LT, EUROCAT Antiepileptic Study Working Group.
Valproic acid monotherapy in pregnancy and major congenital malformations.
N Engl J Med 2010;362(23):2185-93.

23.

Jentink J , Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, de Jong-van den Berg LTW.
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and casecontrol study.
BMJ 2010;341(doi:10.1136/bmj.c6581).

24.

Jentink J , Bakker MK, Nijenhuis CM, Wilffert B, de Jong-van den Berg LTW.
Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?
Pharmacoepidemiology and Drug Safety 2010;19:803-7.

25.

Jentink J, Wang H, de Jong-van den Berg LTW.
Valproic Acid Use in Pregnancy and Congenital Malformations (Reply letter Vajda/O'Brien).
N Engl J Med 2010;363(18):1771-2.

26.

Land JA , van Bergen JE, Morré SA, Postma MJ.
Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening.
Hum Reprod Update 2010;16(2):189-204.

27.

Looijmans-van den Akker I , van Delden JJM, Verheij ThJM, van der Sande MAB, van Essen GA, Riphagen-Dalhuisen J, Hulscher ME, Hak E.
Effects of a multi-faceted program to increase influenza vaccine uptake among health care workers in nursing homes: A cluster randomised controlled trial.
Vaccine 2010;28:5086-92.

28.

Loonen AJM, Stahl SM.
The Mechanism of Drug-induced Akathisia.
CNS Spectr 2010;15:491-4.

29.

Loonen AJM , Stahl SM.
Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders.
Acta Psychiatrica Scandinavica 2010;122:435-7.

30.

Luteijn JM , Hubben GAA, Pechlivanoglou P, Bonten MJ, Postma MJ.
Diagnostic accuracy of culture-based and PCR-based detection tests for MRSA - a meta-analysis.
Clin Microbiol Infect 2010;[Epub ahead of print] PubMed PMID: 20219085.

31.

Mookhoek EJ, van de Kerkhof PCM, Hovens JEJM, Brouwers JRBJ, Loonen AJM.
Substantial skin disorders in psychiatric illness coincide with diabetes and addiction.
Journal European Academy of Dermatolgy and Venereology 2010;DOI:10.1111/j.1468-3083.2010.03797.x.

32.

Mookhoek EJ , van de Kerkhof PCM, Hovens JEJM, Brouwers JRBJ, Loonen AJM.
Skin disorders in chronic psychiatric illness.
Journal European Academy of Dermatolgy and Venereology 2010;DOI: 10.1111/j.1468-3083.2010.03609.x.

33.

Munster JM , Leenders ACAP, van der Hoek W, Schneeberger PM, Rietveld A, Riphagen-Dalhuisen J, Stolk RP, Hamilton CJCM, de Vries E, Meekelenburg J, Lo-Ten-Foe JR, Timmer A, de Jong-van den Berg LTW, Aarnoudse JG, Hak E.
Cost-effectiveness of a screening strategy for Q fever among pregnant women in risk areas: a clustered randomized controlled trial.
BMC Women's Health 2010;DOI:10.1186/1472-6874-10-32.

34.

Opstelten W , van Essen GA, Hak E.
Barriers to Herpes Zoster Vaccination (Hurley L & Kempe A) .
Annals of Internal Medicine 2010;153(6):418-letter.

35.

Pechlivanoglou P , Vehof J, van Agthoven M, de Jong-van den Berg LTW, Postma MJ.
Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
Clin Ther 2010;32(1):108-18.

36.

Postma MJ .
Cost-effectiveness analysis of Human Papillomavirus (HPV) Vaccination in the Netherlands: Recent publication reinforces favorable cost-effectiveness despite misleading conclusion.
Vaccine 2010;28(4):873-4.

37.

Postma MJ , Milne G, Nelson EAS, Pyenson B, Basili M, Coker R, Oxford J, Garrison LP jr, the PI Group.
Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.
Expert Rev Anti Infect Ther 2010;8(12):1431-9.

38.

Risselada AJ , Vehof J, Bruggeman R, Wilffert B, Cohen D, al Hadithy AFY, Arends J, Mulder H.
Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.
The Pharmacogenomics Journal 2010;doi:10.1038/tpj.2010.66.

39.

Rodenburg GD, de Greeff SC, Jansen AGSC, de Melker HE, Schouls LM, Hak E, Spanjaard L, Sanders EAM, van der Ende A. Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands. Emerging Infectious Diseases 2010;16(5):816-23.

40.

Rodenburg GD , van Gils EJM, Veenhoven RH, Jones N, Tcherniaeva I, Hak E, van Alphen L, Berbers GAM, Sanders EAM.
Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses.
Vaccine 2010;28:1391-6.

41.

Roos A , Links TP, de Jong-van den Berg LTW, Gans ROB, Wolffenbuttel BHR, Bakker SJL.
Thyroid peroxidase antibodies, levels of thyroid stimulating hormone and development of hypothyroidism in euthyroid subjects.
European journal of Internal Medicine 2010;DOI:10.1016/j.ejim.2010.09.001.

42.

Rozenbaum MH , Hoek AJ, Hak E, Postma MJ.
Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar).
Vaccine 2010;28(12):2367-9.

43

Rozenbaum MH , Boersma C.
Re: Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands. (Re:1)
Journal of the National Cancer Institute 2010;DOI: 10.1093/jnci/djp519.

44.

Rozenbaum MH , Boersma C.
Re: Cost-effectiveness Analysis of Human Papillomavirus Vaccination in the Netherlands. (Re:2)
Journal of the National Cancer Institute 2010;Correspondence(letter):1.

45.

Rozenbaum MH , Hak E, van der werf TS, Postma MJ.
Results of a Cohort Model Analysis of the Cost-Effectiveness of Routine Immunization With 13-Valent Pneumococcal Conjugate Vaccine of Those Aged ≥65 Years in the Netherlands.
Clinical Therapeutics 2010;32(8):1517-32.

46.

Rozenbaum MH , Sanders EAM, van Hoek AJ, Jansen AGSC, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.
Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
BMJ 2010;doi:10.1136/bmj.c2509.

47.

Rozenbaum MH, Grahlmann C, Postma MJ.
Possible Role of Cost-Effectiveness of HPV Vaccination within the Decision Context on Inclusion of HPV in the Country-Specific National Immunization Programs.
The Open Pharmacoeconomics & Health Economics Journal, 2010 2010;2:1-10.

48.

Rutten FH , Zuithoff NPA, Hak E, Grobbee DE, Hoes AW.
ß-Blockers May Reduce Mortality and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease.
Arch Intern Med 2010;170(10):880-7.

49.

Smink BE , Egberts AC, Lusthof KJ, Uges DRA, de Gier JJ.
The relationship between benzodiazepine use and traffic accidents: A systematic literature review.
Cns Drugs 2010;24(8):639-53.

50.

Taxis K, Barber N.
Safe medication prescribing and administration: three strategies for hospital pharmacists.
EJHP Practice 2010;13(2007/2):98-100.

51.

Toh S , Mitchell AA, Anderka M, de Jong-van den Berg LTW, Hernandez-Diaz S.
National Birth Defects Prevention Study. Antibiotics and oral contraceptive failure - A case-crossover study.
Contraception 2010;DOI:10.1016/j.contraception.2010.08.020.

52.

Tu HA , Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LTW, Postma MJ.
Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
Clin Ther 2010; 32(1):133-44.

53.

van Gelder MMHJ , van Rooij IALM, Miller RK, Zielhuis GA, de Jong-van den Berg LTW, Roeleveld N.
Teratogenic mechanisms of medical drugs.
Human Reproduction Update 2010;DOI:10.1093/humupd/dmp052:1-17.

54.

van Gils EJM , Veenhoven RH, Hak E, Rodenburg GD, Keijzers WCM, Bogaert D, Krzysztof Trzcinski DVM, Bruin JP, van Alphen L, van der Ende A, Sanders EAM.
Pneumococcal Conjugate Vaccination and Nasopharyngeal Acquisition of Pneumococcal Serotype 19A Strains.
JAMA 2010;304(10):1099-106.

55.

van Hulst M , Smit Sibinga CTh, Postma MJ.
Health economics of blood transfusion safety - focus on sub-Saharan Africa.
Biologicals 2010;38(1):53-8.

56.

van Hunsel F , van der Welle C, Passier A, van Puijenbroek EP, van Grootheest AC.
Motives for reporting adverse drug reactions by patient-reporters in the Netherlands.
Eur J Clin Pharmacol 2010;66:1143-50.

57.

van Hunsel F , van Puijenbroek EP, de Jong-van den Berg LTW, van Grootheest AC.
Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins.
Pharmacoepidemiology and Drug Safety 2010;19:26-32.

58.

Vegter S , de Jong-van den Berg LTW.
Misdiagnosis and mistreatment of a common side-effect--angiotensin-converting enzyme inhibitor-induced cough.
Br J Clin Pharmacol 2010;69(2):200-3.

59.

Vegter S , Rozenbaum MH, Postema R, Tolley K, Postma MJ.
Review of Regulatory Recommendations for Orphan Drug Submissions in the Netherlands and Scotland: Focus on the Underlying Pharmacoeconomic Evaluations.
Clinical Therapeutics 2010;32(9):1651-61.

60.

Westra TA , de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ.
Cost-Effectiveness Analysis of Various Pertussis Vaccination Strategies Primarily Aimed at Protecting Infants in the Netherlands.
Clinical Therapeutics 2010;32(8):1479-95.

1.

Blokpoel RGT, Broos N, de Jong-van den Berg LTW, de Vries TW. Waarde omeprazol bij huilende zuigelingen beperkt. Ned Tijdschr Geneesk 2010;154(A1850):1-5.

2.

Boersma C, Broer ACM, Kappelhoff BS, Brouwers JRBJ, van Roon EN, Postma MJ.
Problemen bij subcutane toediening van laagmoleculairgewicht-heparines na totale heup-en knievervangende operaties. Pharmaceutisch Weekblad Wetenschappelijk Platform 2010;4(2):20-4.

3.

de Jong JC, Hak E, Osterhaus ADME. Influenzavaccinatie bij ouderen blijft zinvol. Ned Tijdschr Geneesk 2010;154(A1171):1-5.

4.

de Vries TW, van den Berg PB, Duiverman EJ, de Jong-van den Berg LTW. Farmacotherapieoverleg zinvol bij de behandeling van kinderen met astma. Pharmaceutisch Weekblad Wetenschappelijk Platform 2010;4(11/12):195-7.

5.

Hak E, Knol LM, Wilschut JC, Postma MJ. Influenzavaccinatie van ziekenhuismedewerkers vanuit werkgeversperspectief: batig saldo. Ned Tijdschr Geneesk 2010;154(A1188):1-7.

6.

Postma MJ. Aangeboren afwijkingen geassocieerd met valproïnezuur. Pharmaceutisch Weekblad Wetenschappelijk Platform 2010;4(7/8):146

7.

Schimmel AM, Becker ML, van den Bout T, Taxis K, van den Bemt PMLA. Invloed van twee handmatige medicatie-uitzetmethoden op het aantal toedienfouten. Pharmaceutisch Weekblad Wetenschappelijk Platform 2010;4(3):42-7.

8.

Vroom F, van de Laar MAFJ, van Roon EN, de Walle HEK, de Jong-van den Berg LTW.
Geneesmiddelengebruik tijdens de zwangerschap. Vragen van en antwoorden voor vrouwen met een reumatische aandoening. Pharmaceutisch Weekblad Wetenschappelijk Platform 2010;4(4):56-61.

1.

Bakker MK, de Jong-van den Berg LTW. SSRI’s en zwangerschap.
NedKAD/Silhouet 2010;(herfst):14-6.

2.

Brouwers JRBJ, Piersma-Wichers G, de Jonge Baas U, van Woerkom M. Nieuwe antistollingsmiddelen. Medisch Contact 2010;22:1016-9.

3.

Brouwers JRBJ, Janssen MJA, van Lent-Evers NAEM, de Smet PAGM. Medicatieoverdracht nog lang niet veilig. Spoorboekje moet communicatie stroomlijnen. Medisch Contact 2010;65(41):2142-5.

4.

Loonen AJM. De beste dokter kan het niet alleen. Medisch Contact 2010;36:1794-letter.

5.

van Leen M, Brouwers JRBJ, van der Meer F, ten Cate H. Nieuwe orale antistollingsmiddelen, winst of verlies? Tijdschrift voor Ouderengeneeskunde 2010;4:159-61.

6.

Wyers CE, Huntjens KMB, van den Bergh JPW, Franken AAM, Geusens PPMM, Lems WF, Brouwers JRBJ. Generieke geneesmiddelen voor de behandeling van osteoporose: winst of verlies? Osteoporose Journaal 2010;april:13-20.

1.

1.

de Gier JJ. Contra-indicatie verkeersdeelname.
In: Commentaren Medicatiebewaking 2010/2011. van Buren HCS, Eimermann VM, de Gier JJ, Heringa M, Koekoek CB, Star MC (Eds). Houten: Healt Base, 2011:900-15.

2.

de Gier JJ. Medicinal drugs and driving – recent developments in Europe. In: Faktor Mensch – Zwischen Eignung, Befähigung und Technik. Tagusband 5. Gemeinsames Weimar Symposium. Schubert W, Ditttman V (Eds). Kirschbaum Verlag Bonn, 2010:18-22.

3.

Postma MJ. Sensitivity Analysis. In: Pharmacoeconomics. From theory to practice. Arnold RJG (Ed). Boca Raton: Taylor & Francis Group, 2010:163-74.

4.

van Bodegraven AA, van Weyenberg SJB, Brouwers JRBJ. Maag-,darm- en leverziekten.
In: JJE van Everdingen, Tj Wiersma, JH Gler, eds. Diagnose en Therapie 2010. Bohn Stafleu en van Loghum, 2010:384-415.

5.

Verkes RJ, Loonen AJM. Bijwerking als keuzecriterium. In: RJ Verkes, HG Ruhe. Keuzecriteria voor antidepressiva. Alphen aan den Rijn: Van Zuiden Communications, 2010:83-101.

6.

Welte R, Leidl RM, Greiner W, Postma MJ. Health economics of infectious diseases.
In: Modern Infectious Disease Epidemiolgy. Krämer A, Kretzschmar M, Krickeberg K (Eds). New York: Springer, 2010:249-75.